Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Subjects With Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma

NCT03488251 is registered in ClinicalTrials.gov with Molecular Templates, Inc. as lead sponsor.

NCT NCT03488251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03488251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Subjects With Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma
Lead sponsor
Molecular Templates, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
August 20, 2018
Completion date
March 12, 2021
Enrollment
8 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma,b cell, refractory diffuse large b-cell lymphoma, relapsed diffuse large b-cell lymphoma